The indication for sublobar resection is determined based on radiologic findings, but some cases exhibit radiology-pathology discordance. This study aimed to examine the impact of histologic subtypes on radiology-pathology discordance and their preoperative predictability.
Methods
We reviewed 585 patients with clinical stage IA adenocarcinoma and examined the relationship between radiology-pathology discordance and histologic characteristics, focusing on high-grade components: solid (SOL) or micropapillary (MIP). The predictive ability of radiologic or cytopathologic examinations for those subtypes was evaluated.
Results
Radiology-pathology discordance was found in 148 (25.2%) patients and was significantly associated with the presence of histologic high-grade components, with 71.9% and 70.4% of patients with upstaged lymph node and pleural invasion statuses having high-grade components. The preoperative prediction of high-grade components varied between subtypes, and radiographically pure-solid appearance and high maximum standardized uptake value were independent predictors of the SOL subtype, but not MIP. Among pre- or intraoperative cytopathologic examinations, intraoperative touch imprint cytology exhibited superior detection ability for MIP component.
Conclusions
Histologic high-grade components are highly associated with radiology-pathology discordance in early-stage lung adenocarcinoma. Radiologic assessment would be beneficial for predicting the SOL subtype, but not MIP. Alternatively, intraoperative cytologic assessment would complement the detection of MIP subtype.
{"title":"Clinical Significance and Preoperative Prediction of High-Grade Subtypes in Early-Stage Lung Adenocarcinoma Eligible for Sublobar Resection","authors":"Masashi Mikubo, Satoru Tamagawa, Yasuto Kondo, Dai Sonoda, Masahito Naito, Kazu Shiomi, Masaaki Ichinoe, Yukitoshi Satoh","doi":"10.1002/jso.70117","DOIUrl":"10.1002/jso.70117","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Objectives</h3>\u0000 \u0000 <p>The indication for sublobar resection is determined based on radiologic findings, but some cases exhibit radiology-pathology discordance. This study aimed to examine the impact of histologic subtypes on radiology-pathology discordance and their preoperative predictability.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We reviewed 585 patients with clinical stage IA adenocarcinoma and examined the relationship between radiology-pathology discordance and histologic characteristics, focusing on high-grade components: solid (SOL) or micropapillary (MIP). The predictive ability of radiologic or cytopathologic examinations for those subtypes was evaluated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Radiology-pathology discordance was found in 148 (25.2%) patients and was significantly associated with the presence of histologic high-grade components, with 71.9% and 70.4% of patients with upstaged lymph node and pleural invasion statuses having high-grade components. The preoperative prediction of high-grade components varied between subtypes, and radiographically pure-solid appearance and high maximum standardized uptake value were independent predictors of the SOL subtype, but not MIP. Among pre- or intraoperative cytopathologic examinations, intraoperative touch imprint cytology exhibited superior detection ability for MIP component.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Histologic high-grade components are highly associated with radiology-pathology discordance in early-stage lung adenocarcinoma. Radiologic assessment would be beneficial for predicting the SOL subtype, but not MIP. Alternatively, intraoperative cytologic assessment would complement the detection of MIP subtype.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":"132 8","pages":"1407-1415"},"PeriodicalIF":1.9,"publicationDate":"2025-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145377679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Stockley, C., Bouchard-Fortier, A., Mateshaytis, J., Taqi, K., Mack, L., Nelson, G., Chong, M. and Deban, M. (2025), Implementation of a Multidisciplinary Enhanced Recovery After Surgery (ERAS) Program for Cytoreductive Surgery (CRS) With Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Journal of Surgical Oncology, 131: 527-534. https://doi.org/10.1002/jso.27931.
In the originally published article, the authors missed acknowledging Dr. Golpira Elmi Assadzadeh in the acknowledgment section. The acknowledgment section should read:
“The authors would like to acknowledge Dr. Golpira Elmi Assadzadeh's significant contribution to the data analysis of this study.”
We apologize for this error.
Stockley， C, Bouchard-Fortier， A., Mateshaytis， J., Taqi， K., Mack， L., Nelson， G., Chong， M.和Deban， M.(2025)，细胞减少手术（CRS）与腹腔内高温化疗（HIPEC）的多学科增强术后恢复（ERAS）计划的实施。中华外科杂志，31:527-534。https://doi.org/10.1002/jso.27931.In在最初发表的文章中，作者在致谢部分漏掉了对Golpira Elmi Assadzadeh博士的致谢。致谢部分应该这样写：“作者感谢Golpira Elmi Assadzadeh博士对本研究数据分析的重要贡献。”我们为这个错误道歉。
{"title":"Correction to “Implementation of a Multidisciplinary Enhanced Recovery After Surgery (ERAS) Program for Cytoreductive Surgery (CRS) With Hyperthermic Intraperitoneal Chemotherapy (HIPEC)”","authors":"","doi":"10.1002/jso.70114","DOIUrl":"10.1002/jso.70114","url":null,"abstract":"<p>Stockley, C., Bouchard-Fortier, A., Mateshaytis, J., Taqi, K., Mack, L., Nelson, G., Chong, M. and Deban, M. (2025), Implementation of a Multidisciplinary Enhanced Recovery After Surgery (ERAS) Program for Cytoreductive Surgery (CRS) With Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Journal of Surgical Oncology, 131: 527-534. https://doi.org/10.1002/jso.27931.</p><p>In the originally published article, the authors missed acknowledging Dr. Golpira Elmi Assadzadeh in the acknowledgment section. The acknowledgment section should read:</p><p>“The authors would like to acknowledge Dr. Golpira Elmi Assadzadeh's significant contribution to the data analysis of this study.”</p><p>We apologize for this error.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":"132 8","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jso.70114","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145368361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sameh Hany Emile, Nir Horesh, Zoe Garoufalia, Marcus Oosenbrug, Marylise Boutros, Steven D. Wexner
Background
We assessed predictors of overall (OS) and cancer-specific survival (CSS) in stage I colorectal cancer (CRC).
Methods
Retrospective analysis of patients with stage I colon or rectal adenocarcinomas from the SEER database (2010–2020) Survival was assessed using Kaplan-Meier statistics and multivariable Cox regression analyses. The primary outcomes were 5-year OS and CSS.
Results
40,001 patients (51.3% male; mean age: 65.1 ± 12.6 years) were included. Colon and rectal cancers accounted for 75.8% and 24.2%, respectively. Five-year OS and CSS were 83.1% (95% CI: 82.6–83.5%) and 93.2% (95% CI: 92.9–93.5%), respectively. Factors independently associated with worse OS were age (HR: 1.07; p < 0.001), male sex (HR:1.48; p < 0.001), Black race (HR: 1.25; p < 0.001), single, divorced, or widowed status (HR: 1.49, 1.46, and 1.43; p < 0.001), tumor size (HR: 1.001; p = 0.008), poorly differentiated carcinomas (HR: 1.32; p < 0.001), undifferentiated carcinomas (HR:1.44; p = 0.026), perineural invasion (HR: 1.84; p < 0.001), elevated CEA levels (HR: 1.68; p < 0.001), and systemic therapy (neoadjuvant: HR: 1.3; p = 0.032, adjuvant: HR: 2.2; p < 0.001, both: HR: 1.97; p < 0.001). Factors independently associated with worse CSS were age (HR: 1.05; p < 0.001), male sex (HR: 1.32; p < 0.001), Black race (HR: 1.43; p < 0.001), marital status (HR: 1.44, 1.28, and 1.68; p < 0.001), tumor size (HR: 1.003; p < 0.001), poorly differentiated carcinomas (HR: 1.77; p < 0.001), perineural invasion (HR: 2.29; p < 0.001), elevated CEA levels (HR: 2.24; p < 0.001), and systemic therapy (neoadjuvant: HR: 2.53; p = 0.032, adjuvant: HR: 4.22; p < 0.001, both: HR: 3.83; p < 0.001).
Conclusions
Although patients with stage I CRC had excellent survival, single, older, Black, male patients with large, high-grade tumors associated with perineural invasion and elevated CEA levels had a higher mortality risk.
Approximately 50%–60% of patients with colorectal cancer develop metastases, of which most have unresectable metastatic liver disease. Several recent studies highlight the progress of systemic therapy in converting patients with high burden of colorectal liver metastases (CRLM) from unresectable to resectable disease, resulting in median overall survival improvements. The improvement of systemic therapy and the evolving spectrum of surgical techniques is allowing multidisciplinary treatment teams an increasing ability to achieve complete cytoreduction of CRLM and offering an increasing number of patients a chance for long-term survival.
{"title":"Complete Cytoreduction of Colorectal Liver Metastases: Evolving Systemic Therapy and Liver Transplantation","authors":"Viet Le, Jan Franko, Yuman Fong","doi":"10.1002/jso.70112","DOIUrl":"10.1002/jso.70112","url":null,"abstract":"<div>\u0000 \u0000 <p>Approximately 50%–60% of patients with colorectal cancer develop metastases, of which most have unresectable metastatic liver disease. Several recent studies highlight the progress of systemic therapy in converting patients with high burden of colorectal liver metastases (CRLM) from unresectable to resectable disease, resulting in median overall survival improvements. The improvement of systemic therapy and the evolving spectrum of surgical techniques is allowing multidisciplinary treatment teams an increasing ability to achieve complete cytoreduction of CRLM and offering an increasing number of patients a chance for long-term survival.</p></div>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":"132 8","pages":"1317-1319"},"PeriodicalIF":1.9,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145301553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gabriel De la Cruz Ku, Gonzalo Ziegler-Rodriguez, Anshumi Desai, Luis Piedra Delgado, Jessica Farzan, Jiddu Guart, Michael Mallouh, Camila Franco, Sheila Diaz-Mora, Sandro Casavilca-Zambrano, Jose Cotrina-Concha, Mecker G. Möller
Introduction
Melanoma is a heterogeneous malignancy, the incidence of which has increased by 20% in the Hispanic population over the past two decades. We aimed to compare the clinical, pathological, and outcome-related characteristics of Hispanic patients with melanoma in Peru (HPP) versus the United States (HPUS).
Methods
Two retrospective cohorts were evaluated: HPP diagnosed with melanoma at a tertiary institution in Lima-Peru and HPUS with melanoma registered in the Surveillance, Epidemiology, and End Results Program during the period 2010–2019.
Results
A total of 1136 HPP and 5302 HPUS were included. HPP patients were older (61.17 vs. 56.63 years, p < 0.001), more likely to be male (51.5% vs. 39.6%, p < 0.001), and resided in nonmetropolitan areas (49.6% vs. 3.5%, p < 0.001). HPP had a higher prevalence of primary lesions in the lower extremities (75.5% vs. 36.9%, p < 0.001) and ulceration (65.3% vs. 21.3%, p < 0.001). Histologically, HPP most commonly presented with acral lentiginous melanoma (38.1%), while HPUS had a more superficial spreading type (30.8%, p < 0.001). HPP showed greater Breslow depth (mean: 7.66 vs. 1.51 mm, p < 0.001) and mitotic activity and were diagnosed at more advanced stages: stage III (36.5% vs. 15.0%, p < 0.001). With a median follow-up of 74 months, HPP exhibited worse 5-year overall survival (OS) rates across all stages versus HPUS.
Conclusions
HPP with melanoma exhibit more aggressive pathological features than their HPUS counterparts and are diagnosed at more advanced stages, resulting in poorer OS rates across all stages, and being HPP is a prognostic factor of a worse OS. These findings emphasize the need for further research to deepen our understanding of the molecular factors influencing this diverse biological presentation in Hispanic populations.
{"title":"The Melanoma Divide: Hispanic Health Disparities From Peru to the United States","authors":"Gabriel De la Cruz Ku, Gonzalo Ziegler-Rodriguez, Anshumi Desai, Luis Piedra Delgado, Jessica Farzan, Jiddu Guart, Michael Mallouh, Camila Franco, Sheila Diaz-Mora, Sandro Casavilca-Zambrano, Jose Cotrina-Concha, Mecker G. Möller","doi":"10.1002/jso.70110","DOIUrl":"10.1002/jso.70110","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Melanoma is a heterogeneous malignancy, the incidence of which has increased by 20% in the Hispanic population over the past two decades. We aimed to compare the clinical, pathological, and outcome-related characteristics of Hispanic patients with melanoma in Peru (HPP) versus the United States (HPUS).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Two retrospective cohorts were evaluated: HPP diagnosed with melanoma at a tertiary institution in Lima-Peru and HPUS with melanoma registered in the Surveillance, Epidemiology, and End Results Program during the period 2010–2019.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 1136 HPP and 5302 HPUS were included. HPP patients were older (61.17 vs. 56.63 years, <i>p</i> < 0.001), more likely to be male (51.5% vs. 39.6%, <i>p</i> < 0.001), and resided in nonmetropolitan areas (49.6% vs. 3.5%, <i>p</i> < 0.001). HPP had a higher prevalence of primary lesions in the lower extremities (75.5% vs. 36.9%, <i>p</i> < 0.001) and ulceration (65.3% vs. 21.3%, <i>p</i> < 0.001). Histologically, HPP most commonly presented with acral lentiginous melanoma (38.1%), while HPUS had a more superficial spreading type (30.8%, <i>p</i> < 0.001). HPP showed greater Breslow depth (mean: 7.66 vs. 1.51 mm, <i>p</i> < 0.001) and mitotic activity and were diagnosed at more advanced stages: stage III (36.5% vs. 15.0%, <i>p</i> < 0.001). With a median follow-up of 74 months, HPP exhibited worse 5-year overall survival (OS) rates across all stages versus HPUS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>HPP with melanoma exhibit more aggressive pathological features than their HPUS counterparts and are diagnosed at more advanced stages, resulting in poorer OS rates across all stages, and being HPP is a prognostic factor of a worse OS. These findings emphasize the need for further research to deepen our understanding of the molecular factors influencing this diverse biological presentation in Hispanic populations.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":"132 8","pages":"1376-1390"},"PeriodicalIF":1.9,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145286498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
While peripheral excision margins in cutaneous melanoma are well established, the optimal excision depth remains unclear. In plantar melanoma, the fat pad plays a key functional role, raising concerns about whether full excision is necessary for thin and intermediate-thickness lesions. This study evaluated the association between excision depth and oncologic outcomes in T1–T3 plantar melanoma.
Methods
Patients with primary T1–T3 plantar melanoma who underwent wide excision between 2008 and 2022 were reviewed. They were grouped by excision depth: intra-adiposal (partial fat pad preservation) and suprafascial (complete removal). Oncologic and functional outcomes, assessed via the Foot Function Index (FFI), were compared.
Results
Ninety-four patients (40 intra-adiposal, 54 suprafascial) were analyzed (median follow-up, 43 months). Tumor-free margins were achieved in all cases. Baseline characteristics were similar, except for lesion location. Recurrence rates were comparable, and excision depth was not significantly associated with recurrence-free survival. FFI scores from 26 patients (13 per group) tended to be better in the intra-adiposal group, though not statistically significant.
Conclusions
In thin to intermediate-thickness plantar melanoma, intra-adiposal excision may be oncologically safe if tumor-free margins are achieved, potentially offering functional benefits without compromising oncologic outcomes.
{"title":"Excision Depth and Prognosis in T1–T3 Plantar Melanoma: Is Complete Excision of Plantar Fat Pad Necessary?","authors":"Kyeong-Tae Lee, Sungjin Kim, Goo-Hyun Mun","doi":"10.1002/jso.70108","DOIUrl":"10.1002/jso.70108","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>While peripheral excision margins in cutaneous melanoma are well established, the optimal excision depth remains unclear. In plantar melanoma, the fat pad plays a key functional role, raising concerns about whether full excision is necessary for thin and intermediate-thickness lesions. This study evaluated the association between excision depth and oncologic outcomes in T1–T3 plantar melanoma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients with primary T1–T3 plantar melanoma who underwent wide excision between 2008 and 2022 were reviewed. They were grouped by excision depth: intra-adiposal (partial fat pad preservation) and suprafascial (complete removal). Oncologic and functional outcomes, assessed via the Foot Function Index (FFI), were compared.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Ninety-four patients (40 intra-adiposal, 54 suprafascial) were analyzed (median follow-up, 43 months). Tumor-free margins were achieved in all cases. Baseline characteristics were similar, except for lesion location. Recurrence rates were comparable, and excision depth was not significantly associated with recurrence-free survival. FFI scores from 26 patients (13 per group) tended to be better in the intra-adiposal group, though not statistically significant.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In thin to intermediate-thickness plantar melanoma, intra-adiposal excision may be oncologically safe if tumor-free margins are achieved, potentially offering functional benefits without compromising oncologic outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":"132 8","pages":"1366-1375"},"PeriodicalIF":1.9,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145280601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cristina Taliento, Gennaro Scutiero, Giuseppe Cucinella, Vito Chiantera, Giovanni Pontrelli, Marko Klaric, Dragan Belci, Martin Steinkasserer, Stefano Restaino, Ruby Martinello, Orsola Brasile, Martina Arcieri, Sara Pregnolato, Giulia Pellecchia, Giulia Soraci, Rosa Taratufolo, Carmelia Milano, Marcello Desgro, Francesca Davià, Mariano Catello Di Donna, Dino Becic, Sara Notaro, Giuseppe Vizzielli, Pantaleo Greco
Background and Objectives
This study aims to evaluate the predictive factors associated with failed sentinel lymph node (SLN) mapping in a large, retrospective cohort of patients with early-stage endometrial cancer (EC).
Methods
We retrospectively evaluated a series of EC patients who underwent laparoscopic SLN mapping with intracervical indocyanine green (ICG) injection in five referred oncological centers from January 2019 to March 2024. We compared the clinical and pathological features of bilateral and failed SLN mapping, which was defined as either unilateral mapping or no SLN mapping. Logistic regression was used to identify predictors of failure.
Results
Among 623 analyzed patients, 437 (70.14%) had a successful bilateral procedure. On univariate analysis, age (p = 0.03), non-endometrioid histology (p = 0.02) and previous vaginal delivery (p = 0.015) were significant associated with failed SLN mapping. On multivariable analysis, only increasing age (OR 1.03; 95% CI, 1.01–1.04, p = 0.03) and non-endometrioid histology (OR 1.81; 95% CI, 1.01–3.19) were independently associated with unsuccessful procedure. No significant differences were observed for BMI, enlarged lymph nodes, intraoperative lysis of adhesion, LVSI, grade 3, and FIGO stage.
Conclusions
Increasing age and non-endometrioid histology are independent predictors of bilateral SLN mapping failure in EC patients undergoing SLN mapping with cervical ICG injection.
{"title":"Predictive Factors for Failed Sentinel Lymph Node Mapping in Endometrial Cancer: A Retrospective Multicenter Study","authors":"Cristina Taliento, Gennaro Scutiero, Giuseppe Cucinella, Vito Chiantera, Giovanni Pontrelli, Marko Klaric, Dragan Belci, Martin Steinkasserer, Stefano Restaino, Ruby Martinello, Orsola Brasile, Martina Arcieri, Sara Pregnolato, Giulia Pellecchia, Giulia Soraci, Rosa Taratufolo, Carmelia Milano, Marcello Desgro, Francesca Davià, Mariano Catello Di Donna, Dino Becic, Sara Notaro, Giuseppe Vizzielli, Pantaleo Greco","doi":"10.1002/jso.70106","DOIUrl":"10.1002/jso.70106","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Objectives</h3>\u0000 \u0000 <p>This study aims to evaluate the predictive factors associated with failed sentinel lymph node (SLN) mapping in a large, retrospective cohort of patients with early-stage endometrial cancer (EC).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively evaluated a series of EC patients who underwent laparoscopic SLN mapping with intracervical indocyanine green (ICG) injection in five referred oncological centers from January 2019 to March 2024. We compared the clinical and pathological features of bilateral and failed SLN mapping, which was defined as either unilateral mapping or no SLN mapping. Logistic regression was used to identify predictors of failure.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 623 analyzed patients, 437 (70.14%) had a successful bilateral procedure. On univariate analysis, age (<i>p</i> = 0.03), non-endometrioid histology (<i>p</i> = 0.02) and previous vaginal delivery (<i>p</i> = 0.015) were significant associated with failed SLN mapping. On multivariable analysis, only increasing age (OR 1.03; 95% CI, 1.01–1.04, <i>p</i> = 0.03) and non-endometrioid histology (OR 1.81; 95% CI, 1.01–3.19) were independently associated with unsuccessful procedure. No significant differences were observed for BMI, enlarged lymph nodes, intraoperative lysis of adhesion, LVSI, grade 3, and FIGO stage.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Increasing age and non-endometrioid histology are independent predictors of bilateral SLN mapping failure in EC patients undergoing SLN mapping with cervical ICG injection.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":"132 8","pages":"1391-1398"},"PeriodicalIF":1.9,"publicationDate":"2025-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jso.70106","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145275071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ian S. Reynolds, William P. Duggan, Nicholas P. McKenna, Amit Merchea, Jürgen Mulsow
Background
The use of pressurized intraperitoneal aerosol chemotherapy (PIPAC) is becoming more frequent for patients with unresectable peritoneal metastases. This systematic review explores the indications, protocols, feasibility, safety, oncological outcomes, patient reported outcomes and quality of life outcomes for patients being treated with PIPAC.
Methods
A review of PubMed, Embase and the Cochrane Library was undertaken to identify studies pertaining to patients undergoing treatment with PIPAC. Clinicopathological characteristics, treatment protocols, safety data, treatment response data and outcome data were extracted from relevant studies and included in the analysis.
Results
Data from 1980 patients undergoing 4454 PIPAC procedures for peritoneal metastases from a range of primary cancers was extracted. The treatment protocols identified were relatively homogenous across all studies. Grade 3/4 complications, grade 3/4 toxicity and procedure related mortality occurred infrequently. At least partial histological response was seen in 61.8% of patients. Overall survival for studies presenting data for mixed primary tumors ranged from 8 to 25 months. Quality of life and function were relatively stable throughout treatment.
Conclusions
PIPAC is a safe and feasible treatment option for patients with peritoneal metastases. Ongoing studies are required to evaluate how it compares to best option standard of care chemotherapy.
{"title":"Protocols, Complications, and Outcomes of Pressurized Intraperitoneal Aerosol Chemotherapy for Patients With Peritoneal Metastasis: A Systematic Review of the Literature","authors":"Ian S. Reynolds, William P. Duggan, Nicholas P. McKenna, Amit Merchea, Jürgen Mulsow","doi":"10.1002/jso.70109","DOIUrl":"10.1002/jso.70109","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The use of pressurized intraperitoneal aerosol chemotherapy (PIPAC) is becoming more frequent for patients with unresectable peritoneal metastases. This systematic review explores the indications, protocols, feasibility, safety, oncological outcomes, patient reported outcomes and quality of life outcomes for patients being treated with PIPAC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A review of PubMed, Embase and the Cochrane Library was undertaken to identify studies pertaining to patients undergoing treatment with PIPAC. Clinicopathological characteristics, treatment protocols, safety data, treatment response data and outcome data were extracted from relevant studies and included in the analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Data from 1980 patients undergoing 4454 PIPAC procedures for peritoneal metastases from a range of primary cancers was extracted. The treatment protocols identified were relatively homogenous across all studies. Grade 3/4 complications, grade 3/4 toxicity and procedure related mortality occurred infrequently. At least partial histological response was seen in 61.8% of patients. Overall survival for studies presenting data for mixed primary tumors ranged from 8 to 25 months. Quality of life and function were relatively stable throughout treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>PIPAC is a safe and feasible treatment option for patients with peritoneal metastases. Ongoing studies are required to evaluate how it compares to best option standard of care chemotherapy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":"132 7","pages":"1197-1209"},"PeriodicalIF":1.9,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145274973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Roberta Oliveira de Almeida, Eduardo Soares Rodrigues, Maria Thereza Palmieri Barbosa, Fabrício Tavares Mendonça, Ana Cristina Pinho Mendes Pereira, Catia Sousa Govêia, Larissa Goveia Moreira, Bruno Luís de Castro Araujo, Mauro Pereira de Azevedo, Alexandre Ferreira Oliveira, Rodrigo Nascimento Pinheiro
Anesthetic technique affects surgical outcomes and oncological prognosis. Recognizing the critical role of surgery in cancer treatment, this narrative review aims to improve anesthesiology practices for cancer patients by evaluating actions that positively influence outcomes. Anesthesiologist experience helps guide technique choice in complex cases. Decisions should be customized based on the type of surgery and patient condition, as different techniques can significantly impact results. The expertise of the entire team at specialized centers further enhances outcomes.
{"title":"The Role of Anesthesia in Surgical Oncology: Insights From the Literature and Clinical Considerations","authors":"Roberta Oliveira de Almeida, Eduardo Soares Rodrigues, Maria Thereza Palmieri Barbosa, Fabrício Tavares Mendonça, Ana Cristina Pinho Mendes Pereira, Catia Sousa Govêia, Larissa Goveia Moreira, Bruno Luís de Castro Araujo, Mauro Pereira de Azevedo, Alexandre Ferreira Oliveira, Rodrigo Nascimento Pinheiro","doi":"10.1002/jso.70105","DOIUrl":"10.1002/jso.70105","url":null,"abstract":"<div>\u0000 \u0000 <p>Anesthetic technique affects surgical outcomes and oncological prognosis. Recognizing the critical role of surgery in cancer treatment, this narrative review aims to improve anesthesiology practices for cancer patients by evaluating actions that positively influence outcomes. Anesthesiologist experience helps guide technique choice in complex cases. Decisions should be customized based on the type of surgery and patient condition, as different techniques can significantly impact results. The expertise of the entire team at specialized centers further enhances outcomes.</p>\u0000 </div>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":"132 7","pages":"1210-1217"},"PeriodicalIF":1.9,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145251461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号